Lucid Group, a global healthcare consultancy, completed the acquisition of Synetic Life Sciences, a specialist consulting firm focused on the life sciences including biopharma companies, providers and investors. Financial terms were not disclosed. “Our goal has been to purposefully design an organisation with the capabilities to have a transformational impact for clients’ organisations, for their medicines and for the patients who will ultimately benefit from them. We have been searching for a consultancy with the right capability, ambition and culture to help make this a reality. I believe we have created an entirely new proposition, an end-to-end partnership which can disrupt the standard agency model, challenge traditional thinking and bring something genuinely exciting to our clients,” Dennis O’Brien, Lucid Group CEO.